NasdaqCM - Delayed Quote USD

Celularity Inc. (CELUW)

0.0498
+0.0098
+(24.50%)
At close: June 9 at 4:00:00 PM EDT
Loading Chart for CELUW
  • Previous Close 0.0400
  • Open 0.0372
  • Bid --
  • Ask --
  • Day's Range 0.0372 - 0.0499
  • 52 Week Range 0.0372 - 0.0499
  • Volume 690
  • Avg. Volume --
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 0.76
  • PE Ratio (TTM) --
  • EPS (TTM) -0.8700
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBankin. Its lead therapeutic programs include CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. In addition, the company is developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. Celularity Inc. produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is based in Florham Park, New Jersey.

www.celularity.com

123

Full Time Employees

--

Fiscal Year Ends

Recent News: CELUW

View More

Compare To: CELUW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CELUW

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -106.77%

  • Return on Assets (ttm)

    -17.42%

  • Return on Equity (ttm)

    -232.51%

  • Revenue (ttm)

    54.22M

  • Net Income Avi to Common (ttm)

    -57.89M

  • Diluted EPS (ttm)

    -0.8700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    738k

  • Total Debt/Equity (mrq)

    778.95%

  • Levered Free Cash Flow (ttm)

    10.32M

Research Analysis: CELUW

View More

Company Insights: CELUW

Research Reports: CELUW

View More

People Also Watch